Market
How will the market react to Stryker's acquisition of Inari Medical by March 31, 2025?
3
Resolution / Starting Odds
Positive • 25%
Neutral • 25%
Negative • 25%
Unchanged • 25%
Analysis from financial news and stock market data
Story
Stryker to Acquire Inari Medical for $4.9 Billion at $80 Per Share, Targeting VTE Treatments
Jan 6, 2025, 08:22 PM
Stryker Corp. has announced a definitive agreement to acquire Inari Medical, Inc. for $80 per share in cash, valuing the deal at approximately $4.9 billion. The acquisition aims to expand Stryker's portfolio into the high-growth peripheral vascular segment, particularly targeting venous thromboembolism (VTE) treatments. Inari's innovative product offerings, which include mechanical thrombectomy solutions for conditions like deep vein thrombosis and pulmonary embolism, are seen as complementary to Stryker's existing Neurovascular business. The transaction is expected to close by the end of the first quarter of 2025, pending customary closing conditions including regulatory approvals.
View original story
Similar markets
Yes • 50%
No • 50%
5-10% • 25%
10-15% • 25%
More than 15% • 25%
Less than 5% • 25%
Increase by 0-10% • 25%
No change • 25%
Increase by more than 10% • 25%
Decrease • 25%
Increase by more than 5% • 25%
Decrease • 25%
No significant change • 25%
Increase by 1-5% • 25%
J&J stock remains within 5% of current price • 25%
J&J stock rises by more than 5% • 25%
J&J stock falls by more than 5% • 25%
Other • 25%
Increases by more than 50% • 25%
Decreases by more than 10% • 25%
Remains stable (±10%) • 25%
Increases by 30-50% • 25%
No significant increase • 25%
Increase by less than 5% • 25%
Increase by 5-10% • 25%
Increase by more than 10% • 25%
